Generic Plaquenil (hydroxychloroquine) COVID-19 Shows Best Results

For the treatment of COVID-19, Plaquenil recommends the well-known French infectious diseases doctor, head of the Mediterranean Institute of Infectious Diseases in Marseille, Didier Rault. He conducted a small clinical study involving 36 patients with COVID-19 (some dropped out for various reasons). In patients taking Plaquenil, the viral load significantly decreased on the sixth day. The antiviral effect was enhanced when taking Plaquenil along with the antibiotic azithromycin.

HYDROXYCHLOROQUINE SULFAT

• Oral consent of the patient is required, which must be recorded in the medical history.

• COMMERCIAL DRUGS:


Dolkin, Plaquenil: 200 mg tablets.

• DOSAGE:


or 400 mg / 12 hours (2 tablets) two doses, and then 200 mg / 12 hours. The duration of treatment is individual, depending on the course of the disease. Duration from 5-14 days.

• CONTRAINDICATIONS:

concomitant treatment:
o Natalizumab (multiple sclerosis): increased toxicity (risk of infection)
o Agalsidalsa α or β (Fabry disease): the intracellular activity of galactosidase alpha and beta is inhibited.
o Cautious administration with dosage adjustment of hypoglycemic drugs, digoxin, beta-blockers and antipsychotics (chlorpromazine, levomepromazine): enhances their effect.
o Caution with myasthenia gravis, epilepsy, liver damage, renal failure, deficiency of 6-P-dehydrogenase.

• INTERACTIONS / PRECAUTIONS:


o Antacids: they can reduce the absorption of hydroxychloroquine → the interval between doses of at least 4 hours.
o Aminoglycosides: risk of neuromuscular blockade.
o Trastuzumab (breast / stomach cancer): increases the risk of neutropenia.
o Dapsone: risk of hemolysis.
o Hydroxychloroquine may reduce the effects of neostigmine and pyridostigmine.
o The effect of tacrolimus may increase with an increase in the QT interval.

LOPINAVIR / RITONAVIR

• Oral consent of the patient is required, which must be recorded in the medical history
• Serology of HIV infection must be performed, although there is no need to wait for the result to begin treatment.

• COMMERCIAL DRUGS:


o KALETRA: 200/50 mg, coated tablets 100/25 mg.
o KALETRA: oral solution 80 mg / 20 mg / ml.
o LOPINAVIR / RITONAVIR ACCORD: coated tablets with 200 mg / 50 mg.

• DOSAGE:


400 mg / 100 mg (200 mg / 50 mg capsules) two capsules (or 5 ml of solution) orally twice a day. The duration of treatment is individual, depending on the course of the disease. Duration 5-14 days.

• SIDE EFFECTS:
o Frequent: diarrhea, nausea, vomiting, hypertriglyceridemia, and hypercholesterolemia.
o Rarely: pancreatitis, prolongation of the QT interval on the ECG.

• INTERACTIONS / PRECAUTIONS:
Both active ingredients are inhibitors of the CYP3A P450 isoform. Lopinavir / ritonavir should not be used together with drugs whose metabolism is highly dependent on CYP3A and for which an increase in plasma concentration is associated with serious and / or life-threatening complications. See the datasheet for the complete list (https://cima.aemps.es/cima/dochtml/ft/80104/FT_80104.html).

Interaction Consulting Tool: https://www.hiv-druginteractions.org/checker.
Statins: atorvastatin: maximum 10 mg / day with lopinavir / ritonavir (use only when statin is considered necessary).

Web Analytics